BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 McGarry ME, McColley SA, Taylor-Cousar J. In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies". Respir Med 2022;202:106953. [PMID: 36049345 DOI: 10.1016/j.rmed.2022.106953] [Reference Citation Analysis]
2 Despotes KA, Donaldson SH. Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology 2022;65:102239. [DOI: 10.1016/j.coph.2022.102239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 McColley SA, Martiniano SL, Ren CL, Sontag MK, Rychlik K, Balmert L, Elbert A, Wu R, Farrell PM. Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening. J Cyst Fibros 2022:S1569-1993(22)00628-2. [PMID: 35871976 DOI: 10.1016/j.jcf.2022.07.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mayer-Hamblett N, Zemanick ET, Odem-Davis K, VanDevanter D, Warden M, Rowe SM, Young J, Konstan MW, For-The-Chec-Sc-Study-Group. Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study. J Cyst Fibros 2022:S1569-1993(22)00625-7. [PMID: 35871974 DOI: 10.1016/j.jcf.2022.07.008] [Reference Citation Analysis]
5 Vaidyanathan S, Trumbull AM, Bar L, Rao M, Yu Y, Sellers ZM. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis. Genet Med 2022:S1098-3600(22)00818-8. [PMID: 35857025 DOI: 10.1016/j.gim.2022.06.009] [Reference Citation Analysis]
6 Jaganathan D, Bruscia EM, Kopp BT. Emerging Concepts in Defective Macrophage Phagocytosis in Cystic Fibrosis. IJMS 2022;23:7750. [DOI: 10.3390/ijms23147750] [Reference Citation Analysis]
7 Phadke MY, Sellers ZM. Current clinical opinion on CFTR dysfunction and patient risk of pancreatitis: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol 2022;:1-11. [PMID: 35623009 DOI: 10.1080/17474124.2022.2084072] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Soder SA, Fontena E, Salgado JC, Shahmohammadi A, Samano MN, Machuca TN. Inpatient Management of the Acutely Decompensating Lung Transplant Candidate. Thorac Surg Clin 2022;32:121-34. [PMID: 35512931 DOI: 10.1016/j.thorsurg.2022.02.001] [Reference Citation Analysis]
9 Knoppers T, Cosquer M, Hagan J, Nguyen MT, Knoppers BM. “The Stakes Are Higher”- Patient and Caregiver Perspectives on Cystic Fibrosis Research and Personalized Medicine. Front Med 2022;9:841887. [DOI: 10.3389/fmed.2022.841887] [Reference Citation Analysis]
10 South K, George M, Sadeghi H, Piane V, Smaldone A. Moving up: Healthcare transition experiences of adolescents and young adults with cystic fibrosis. Journal of Pediatric Nursing 2022. [DOI: 10.1016/j.pedn.2022.03.007] [Reference Citation Analysis]
11 Reeves SR. Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment. Eur Respir J 2021;58:2102735. [PMID: 34857588 DOI: 10.1183/13993003.02735-2021] [Reference Citation Analysis]
12 Perez AA, Leard LE. What's in a name: The importance of lung transplant at Cystic Fibrosis Foundation Accredited Care Centers for patients with Cystic Fibrosis. J Heart Lung Transplant 2021:S1053-2498(21)02612-7. [PMID: 34973873 DOI: 10.1016/j.healun.2021.11.015] [Reference Citation Analysis]
13 Mcgarry ME, Gibb ER, Oates GR, Schechter MS. Left Behind: The Potential Impact of CFTR Modulators on Racial and Ethnic Disparities in Cystic Fibrosis. Paediatric Respiratory Reviews 2021. [DOI: 10.1016/j.prrv.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med 2021;27:554-66. [PMID: 34420018 DOI: 10.1097/MCP.0000000000000819] [Reference Citation Analysis]
15 McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol 2021. [PMID: 34672432 DOI: 10.1002/ppul.25733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rowbotham NJ, Daniels TE. Airway clearance and exercise for people with cystic fibrosis: Balancing longevity with life. Pediatr Pulmonol 2021. [PMID: 34672434 DOI: 10.1002/ppul.25734] [Reference Citation Analysis]
17 Wright M, Wright T. Health disparity in CF: Perspectives from a lived experience. Pediatr Pulmonol 2021. [PMID: 34647698 DOI: 10.1002/ppul.25727] [Reference Citation Analysis]
18 Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2021. [PMID: 34473419 DOI: 10.1002/ppul.25660] [Reference Citation Analysis]
19 Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med 2021;203:1522-32. [PMID: 33734030 DOI: 10.1164/rccm.202102-0509OC] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
20 Daines CL, Morgan WJ. The Future of Highly Effective Modulator Therapy in Cystic Fibrosis. Am J Respir Crit Care Med 2021;203:1453-5. [PMID: 33901406 DOI: 10.1164/rccm.202104-0850ED] [Reference Citation Analysis]
21 Guimbellot JS, Taylor-Cousar JL. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med 2021;9:677-9. [PMID: 33965001 DOI: 10.1016/S2213-2600(21)00176-4] [Reference Citation Analysis]
22 Keegan DE, Brewington JJ. Nasal Epithelial Cell-Based Models for Individualized Study in Cystic Fibrosis. Int J Mol Sci 2021;22:4448. [PMID: 33923202 DOI: 10.3390/ijms22094448] [Reference Citation Analysis]